Anika Historical Financial Ratios

ANIK Stock  USD 16.25  0.02  0.12%   
Anika Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.73 or Days Sales Outstanding of 54.36 will help investors to properly organize and evaluate Anika Therapeutics financial condition quickly.
Quick RatioCurrent Ratio100%
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

About Anika Financial Ratios Analysis

Anika TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Anika Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Anika financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Anika Therapeutics history.

Anika Therapeutics Financial Ratios Chart

At this time, Anika Therapeutics' EV To Sales is quite stable compared to the past year. Inventory Turnover is expected to rise to 1.48 this year, although the value of Operating Cash Flow Per Share is projected to rise to (0.12).
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
JavaScript chart by amCharts 3.21.15201520202.02.53.03.54.04.55.05.56.06.57.0 1.41.61.82.02.22.42.62.83.03.23.43.63.84.0 556065707580859095 9101112131415161718192021 123456789 -0.5-0.4-0.3-0.2-0.100.10.20.3
JavaScript chart by amCharts 3.21.15Price To Sales Ratiototal: 60.32530306642172Ptb Ratiototal: 29.577081936223504Days Sales Outstandingtotal: 909.9531120454596Book Value Per Sharetotal: 196.1999244286839Tangible Asset Valuetotal: 0Net Profit Margintotal: 0.7606549192772749

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Anika Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Anika Therapeutics sales, a figure that is much harder to manipulate than other Anika Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Tangible Asset Value

The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.

Net Profit Margin

The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.
Most ratios from Anika Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' EV To Sales is quite stable compared to the past year. Inventory Turnover is expected to rise to 1.48 this year, although the value of Operating Cash Flow Per Share is projected to rise to (0.12).
 2021 2022 2023 2024 (projected)
Days Sales Outstanding73.780.978.7654.36
PTB Ratio1.81.511.561.73

Anika Therapeutics fundamentals Correlations

0.89-0.120.190.130.74-0.360.360.890.980.670.56-0.490.60.28-0.010.370.070.60.310.170.260.330.10.290.52
0.890.030.140.330.69-0.210.091.00.940.660.58-0.270.52-0.020.240.42-0.20.440.240.370.290.29-0.170.240.56
-0.120.03-0.10.560.120.46-0.140.03-0.020.110.470.720.33-0.750.17-0.07-0.4-0.020.290.340.50.11-0.40.230.49
0.190.14-0.10.370.29-0.27-0.360.140.30.240.0-0.36-0.04-0.080.070.9-0.560.720.19-0.460.410.1-0.420.050.06
0.130.330.560.370.620.42-0.590.330.270.680.640.520.43-0.820.50.52-0.870.460.280.130.620.2-0.70.450.67
0.740.690.120.290.62-0.070.020.690.750.980.81-0.10.79-0.150.270.48-0.290.80.410.010.510.29-0.190.590.8
-0.36-0.210.46-0.270.42-0.07-0.33-0.21-0.30.010.20.790.07-0.640.02-0.25-0.34-0.290.050.360.180.02-0.230.170.21
0.360.09-0.14-0.36-0.590.02-0.330.090.22-0.140.04-0.430.250.66-0.42-0.330.830.00.06-0.2-0.190.090.69-0.02-0.01
0.891.00.030.140.330.69-0.210.090.940.660.58-0.270.52-0.020.240.42-0.20.440.240.370.290.29-0.170.240.56
0.980.94-0.020.30.270.75-0.30.220.940.690.59-0.420.580.130.060.48-0.10.640.340.210.350.34-0.060.290.56
0.670.660.110.240.680.980.01-0.140.660.690.810.00.76-0.230.340.41-0.360.720.40.110.490.28-0.260.60.79
0.560.580.470.00.640.810.20.040.580.590.810.30.94-0.420.390.18-0.240.460.720.240.770.31-0.280.530.98
-0.49-0.270.72-0.360.52-0.10.79-0.43-0.27-0.420.00.30.16-0.850.34-0.34-0.41-0.40.140.380.290.07-0.420.230.34
0.60.520.33-0.040.430.790.070.250.520.580.760.940.16-0.210.280.080.00.480.750.150.70.42-0.10.660.95
0.28-0.02-0.75-0.08-0.82-0.15-0.640.66-0.020.13-0.23-0.42-0.85-0.21-0.52-0.170.790.05-0.22-0.32-0.53-0.140.73-0.31-0.48
-0.010.240.170.070.50.270.02-0.420.240.060.340.390.340.28-0.520.25-0.460.090.16-0.010.310.17-0.790.20.42
0.370.42-0.070.90.520.48-0.25-0.330.420.480.410.18-0.340.08-0.170.25-0.650.730.14-0.360.430.11-0.470.110.22
0.07-0.2-0.4-0.56-0.87-0.29-0.340.83-0.2-0.1-0.36-0.24-0.410.00.79-0.46-0.65-0.32-0.04-0.08-0.43-0.050.8-0.16-0.29
0.60.44-0.020.720.460.8-0.290.00.440.640.720.46-0.40.480.050.090.73-0.320.31-0.370.450.23-0.220.420.47
0.310.240.290.190.280.410.050.060.240.340.40.720.140.75-0.220.160.14-0.040.310.080.890.29-0.170.30.74
0.170.370.34-0.460.130.010.36-0.20.370.210.110.240.380.15-0.32-0.01-0.36-0.08-0.370.080.040.02-0.080.160.22
0.260.290.50.410.620.510.18-0.190.290.350.490.770.290.7-0.530.310.43-0.430.450.890.040.22-0.460.350.8
0.330.290.110.10.20.290.020.090.290.340.280.310.070.42-0.140.170.11-0.050.230.290.020.22-0.150.590.4
0.1-0.17-0.4-0.42-0.7-0.19-0.230.69-0.17-0.06-0.26-0.28-0.42-0.10.73-0.79-0.470.8-0.22-0.17-0.08-0.46-0.15-0.16-0.34
0.290.240.230.050.450.590.17-0.020.240.290.60.530.230.66-0.310.20.11-0.160.420.30.160.350.59-0.160.63
0.520.560.490.060.670.80.21-0.010.560.560.790.980.340.95-0.480.420.22-0.290.470.740.220.80.4-0.340.63
Click cells to compare fundamentals

Anika Therapeutics Account Relationship Matchups

Anika Therapeutics fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio6.394.933.492.761.993.33
Ptb Ratio2.542.361.81.511.561.73
Days Sales Outstanding73.567.4373.780.978.7654.36
Book Value Per Share20.4219.1519.9419.6114.4815.21
Free Cash Flow Yield0.04670.01780.006306(0.007139)(0.0217)(0.0228)
Stock Based Compensation To Revenue0.05310.04130.0750.09160.09150.0869
Capex To Depreciation0.790.470.120.360.520.38
Pb Ratio2.542.361.81.511.561.73
Ev To Sales3.755.24.362.982.41.73
Free Cash Flow Per Share2.420.80.23(0.21)(0.49)(0.47)
Roic0.0894(0.0445)(0.11)(0.0538)(0.4)(0.38)
Inventory Turnover1.311.331.81.581.371.48
Net Income Per Share1.93(1.69)0.29(1.02)(5.64)(5.36)
Days Of Inventory On Hand279.27274.56202.67231.63266.32285.53
Payables Turnover7.56.848.56.916.456.22
Capex To Revenue0.02470.01250.03480.04790.03260.0309
Cash Per Share13.16.916.555.934.973.5
Pocfratio19.7949.2761.4597.76(185.74)(176.45)
Capex To Operating Cash Flow0.07640.120.611.7(3.04)(2.88)
Pfcf Ratio21.4256.28158.57(140.07)(46.03)(43.73)
Days Payables Outstanding48.6553.3842.9652.8656.6180.78
Income Quality1.36(0.54)2.03(0.3)0.02160.0205
Roe0.0943(0.088)0.0144(0.052)(0.39)(0.37)
Ev To Operating Cash Flow16.1143.5352.585.18(161.23)(153.17)
Pe Ratio26.93(26.84)124.82(29.01)(4.02)(3.82)
Return On Tangible Assets0.0862(0.0901)0.0161(0.0556)(0.32)(0.3)
Ev To Free Cash Flow17.4449.73135.48(122.06)(39.95)(37.96)
Earnings Yield0.0371(0.0373)0.008012(0.0345)(0.25)(0.24)
Intangibles To Total Assets0.04620.270.260.230.04510.0428
Net Debt To E B I T D A(3.97)5.84(28.74)11.283.94.1
Current Ratio14.484.815.666.075.267.0
Tangible Book Value Per Share19.3412.1513.6713.9813.6514.33
Receivables Turnover4.975.414.954.514.637.3
Graham Number29.7526.9611.3521.2242.8745.02

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…